Corbus Pharmaceuticals
CRBP
107 hedge funds and large institutions have $88.5M invested in Corbus Pharmaceuticals in 2021 Q1 according to their latest regulatory filings, with 20 funds opening new positions, 37 increasing their positions, 22 reducing their positions, and 19 closing their positions.
73% more capital invested
Capital invested by funds: $51.2M → $88.5M (+$37.3M)
68% more repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 22
8% more call options, than puts
Call options by funds: $2.56M | Put options by funds: $2.38M
5% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 19
0% more funds holding
Funds holding: 107 → 107 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.39% less ownership
Funds ownership: 1.56% → 1.17% (-0.39%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$7.04M |
| 2 |
IEFM
IQ EQ Fund Management
Dublin 2,
Ireland
|
+$4.61M |
| 3 |
Mirae Asset Global Investments
Seoul,
South Korea
|
+$2.95M |
| 4 |
IC
Ikarian Capital
Dallas,
Texas
|
+$1.81M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$1.12M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EMG
ETF Managers Group
Summit,
New Jersey
|
-$4.56M |
| 2 |
D.E. Shaw & Co
New York
|
-$3.36M |
| 3 |
HF
HRT Financial
New York
|
-$1.68M |
| 4 |
Renaissance Technologies
New York
|
-$1.2M |
| 5 |
Squarepoint
New York
|
-$363K |
CRBP Hedge Fund Activity: Q1 2021 in Review
107 of the 5,711 institutional investors tracked by Wall St. Rank reported a position in Corbus Pharmaceuticals (CRBP) for Q1 2021, worth a combined $88.5M — up 73% from $51.2M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new CRBP positions and 19 closed out — a net gain of 1 holder — while 37 added to existing stakes and 22 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $7.04M. The largest seller was ETF Managers Group, cutting an estimated $4.56M.
- 107 institutional investors held Corbus Pharmaceuticals (CRBP) as of Q1 2021, unchanged from Q4 2020.
- Funds reported $88.5M of Corbus Pharmaceuticals stock for Q1 2021, up 73% quarter-over-quarter.
- 20 funds opened new Corbus Pharmaceuticals positions in Q1 2021 and 19 closed out, a net change of +1 holder.
- The largest Corbus Pharmaceuticals buyer in Q1 2021 was Morgan Stanley, an estimated $7.04M added.
- The largest Corbus Pharmaceuticals seller in Q1 2021 was ETF Managers Group, an estimated $4.56M sold.
Based on aggregated 13F filings for Q1 2021.